Entrada Therapeutics, Inc. (NASDAQ:TRDA) Holdings Raised by Strs Ohio

Strs Ohio grew its position in Entrada Therapeutics, Inc. (NASDAQ:TRDA) by 792.6% in the fourth quarter, Holdings Channel.com reports. The fund owned 24,100 shares of the company’s stock after buying an additional 21,400 shares during the period. Strs Ohio’s holdings in Entrada Therapeutics were worth $363,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also made changes to their positions in TRDA. TD Asset Management Inc increased its holdings in shares of Entrada Therapeutics by 100.0% in the 3rd quarter. TD Asset Management Inc now owns 119,254 shares of the company’s stock valued at $1,884,000 after acquiring an additional 59,627 shares during the last quarter. Wellington Management Group LLP increased its holdings in shares of Entrada Therapeutics by 2.6% in the 3rd quarter. Wellington Management Group LLP now owns 1,045,652 shares of the company’s stock valued at $16,521,000 after acquiring an additional 26,144 shares during the last quarter. SG Americas Securities LLC bought a new stake in shares of Entrada Therapeutics in the 3rd quarter valued at approximately $145,000. Finally, Allspring Global Investments Holdings LLC bought a new stake in shares of Entrada Therapeutics in the 3rd quarter valued at approximately $44,000. 86.39% of the stock is currently owned by institutional investors.

Entrada Therapeutics Price Performance

Shares of TRDA opened at $12.45 on Monday. The company has a market cap of $418.32 million, a P/E ratio of -47.88 and a beta of -0.50. The stock has a fifty day moving average price of $13.08 and a 200 day moving average price of $14.25. Entrada Therapeutics, Inc. has a 12 month low of $10.62 and a 12 month high of $18.44.

Entrada Therapeutics (NASDAQ:TRDA) last issued its quarterly earnings data on Wednesday, March 13th. The company reported ($0.29) EPS for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.22). The company had revenue of $41.85 million for the quarter, compared to the consensus estimate of $27.82 million. Entrada Therapeutics had a negative return on equity of 2.89% and a negative net margin of 5.18%. As a group, research analysts anticipate that Entrada Therapeutics, Inc. will post -1.54 earnings per share for the current year.

Wall Street Analysts Forecast Growth

TRDA has been the subject of a number of research analyst reports. HC Wainwright reiterated a “buy” rating and issued a $20.00 price target on shares of Entrada Therapeutics in a report on Monday, March 18th. Oppenheimer assumed coverage on Entrada Therapeutics in a research note on Friday, January 5th. They set an “outperform” rating and a $22.00 price objective for the company.

Insiders Place Their Bets

In other Entrada Therapeutics news, Director Peter S. Kim purchased 3,180 shares of Entrada Therapeutics stock in a transaction on Monday, March 25th. The stock was bought at an average price of $13.36 per share, for a total transaction of $42,484.80. Following the transaction, the director now owns 56,074 shares of the company’s stock, valued at approximately $749,148.64. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In other news, Director Peter S. Kim acquired 2,600 shares of the business’s stock in a transaction dated Monday, April 8th. The stock was acquired at an average price of $13.57 per share, for a total transaction of $35,282.00. Following the completion of the acquisition, the director now directly owns 62,936 shares in the company, valued at approximately $854,041.52. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Peter S. Kim acquired 3,180 shares of the business’s stock in a transaction dated Monday, March 25th. The stock was purchased at an average price of $13.36 per share, with a total value of $42,484.80. Following the acquisition, the director now owns 56,074 shares of the company’s stock, valued at $749,148.64. The disclosure for this purchase can be found here. In the last quarter, insiders acquired 8,896 shares of company stock worth $119,272. 7.58% of the stock is owned by company insiders.

About Entrada Therapeutics

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.